ADC Pipeline Focus Will Advance Preclinical Drug Development

Published
03 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$3.11
72.5% undervalued intrinsic discount
15 Aug
US$0.86
Loading
1Y
-82.9%
7D
-2.3%

Author's Valuation

US$3.1

72.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 14%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 12%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 43.3x to 48.6x.

Shared on09 Apr 25